Clinical trials: MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Pseudomonas Aeruginosa
Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects
Clinical trial looking to evaluate the efficacy and safety of MEDI3902 in mechanically ventilated participants for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa.
- Trial name
- EVADE (NCT02696902)
- Testing
- MEDI3902
- Where
- 78 sites in United States, Austria and 12 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
MEDI3902 for Prevention of P. Aeruginosa Pneumonia
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
- Trial name
- NCT02255760
- Testing
- MEDI3902 - Dose 1, MEDI3902 - Dose 2, MEDI3902 - Dose 3
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC